The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

Completed · Phase 2 · Has a placebo group

Conditions studied: End Stage Renal Disease

In brief

The purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the study will permit investigators to assess the variability of serum uremic retention solute concentrations with and without antibiotic over a three-month period.

Key facts

Study ID

NCT03452189

Run by

NYU Langone Health

People needed

15

Starts

2017-11-27

Expected to finish

2018-08-18

Last updated by the study team

2021-03-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with stable chronic kidney disease on hemodialysis with a fistula or an AV graft.

You may not qualify if…

• Antibiotics received within the last 3 months;
• recent diarrhea
• known allergy to vancomycin
• history of C. difficile infection
• elevation of white blood cell count or fever within one week of enrollment.

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.